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Abstract 
 
The complexes formed between 4-hydroxy-5-methyl-3-pyridinecarboxylic acid (DQ5) and 
1,5-dimethyl-4-hydroxy-3-pyridinecarboxylic acid (DQ715) and Cu(II) and Zn(II) were 
investigated in aqueous solution. The proton dissociation constants of the ligands, the stability 
constants, and the coordination modes of the metal complexes formed were determined by 
pH-potentiometric, and spectral (UV-vis and EPR or 1H NMR) methods. The results show 
that in the pH range between 2 and 10 mono an bis complex formed through bidentate 
coordination of the ligands. The biological MTT-test reveals that the DQ715 ligand is able to 
lower the cytotoxic effect of Cu(II) in human embryonic kidney HEK-293 cells. 
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Graphical abstract 
 
The complex formation have been characterized by pH-potentiometric and spectral (UV-vis 
and EPR and 1H NMR) methods between two hydroxy pyridine carboxylic acids and Cu(II) 
and Zn(II) ions. 
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1. Introduction 
 
Many transition metal ions, such a copper, iron and zinc, are essential for all living organisms. 
It is estimated that more than one-third of enzymes contain metal ions [1]. Furthermore they 
participate in a wide variety of biochemical processes in the cells. The equilibrium 
distribution of metal ions is crucial for many physiological functions.  
Homeostasis of metal ions is critical for life and is maintained within strict limits [2]. In 
particular the redox active metals likely play a major role in altered redox balance. These 
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metals, especially iron and copper, can undergo redox cycling and cause oxidative stress by 
increasing the formation of reactive oxygen species (ROS) as superoxide ion, hydrogen 
peroxide, and hydroxyl radical, resulting in the damage of many biomolecules in the cells. 
Copper (Cu) is an essential trace metal used as a catalytic cofactor for many enzymes [3,4,5]. 
Copper ion exists in Cu(I) and Cu(II) oxidation states and can undergo electron transfer 
reactions in living systems in a similar way as for Fe(III)/Fe(II). In the reductive environment 
of the cell, Cu(II) can be reduced to Cu(I) by ascorbate or glutathione, and the reduced 
copper(I) can be oxidised to Cu(II) through the Fenton-type reaction[6,7]. The reduced metal 
ions such as Fe(II) and Cu(I) generate extremely reactive hydroxyl radicals from hydrogen 
peroxide in M(red) + H2O2 →  M(ox) + OH• + OH– reaction [6,7]. Copper excess or 
deficiency can cause impaired cellular functions and eventually cell death [3]. Copper 
deficiency causes impaired energy production, abnormal glucose and cholesterol metabolism, 
increased oxidative damage, increased tissue iron (Fe), altered structure and function of 
circulating blood and immune cells, abnormal neuropeptide synthesis and processing, aberrant 
cardiac electrophysiology, impaired myocardial contractility, and persistent effects on 
neurobehavior and on the immune system [8,9,10]. Nowadays it appears that the copper 
excess causes even more significant health problems. Some scientists believe that 
environmental factors are responsible for the increased copper uptake. The metal ion might be 
more bioavailable because it is leached from copper plumbing in homes or ingested as 
inorganic copper from vitamin/mineral supplements [16]. Cu overload is implicated in the 
pathogenesis of a variety of human diseases like cancer, cirrhosis, atherogenesis and 
neurodegenerative diseases [5]. Copper can also play a key role in the copper metabolism 
disorders as Menkes [11] and Wilson [12] diseases, and neurodegenerative disorders like 
familial amyotrophic lateral sclerosis or prion diseases [13]. Several studies indicate that the 
homeostasis of Cu(II) may become abnormal with aging. The copper level in the plasma is 
higher when compared to reference values obtained from healthy adults [14,15]. Many 
mechanisms have been demonstrated to influence the Alzheimer disease (AD), and they 
evidence that copper has a dramatic influence in the development of AD [16] and plays 
critical roles in the β-amyloid plaque formation in the Alzheimer’s brain. The interaction of 
copper with amyloid precursor protein or Aβ-peptide (Aβ) can produce neurotoxic H2O2 
(through the reduction of Cu(II)) and lead to oxidative stress in brain [17,18,19]. Some 
selective ligands for Cu(II) have been proposed as chelating agents for the therapy of AD. The 
first was clioquinol (CQ), which could chemically solubilize Aβ deposits in AD [20] likely 
through the interaction with copper. Faller and coworkers suggested that a chelator with a 
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conditional dissociation constant (KD) of 1 pM for Cu(II) should be sufficient to retrieve 
copper completely from amyloid deposits [21]. Other results show that an αB-crystallin 
chaperon peptide prevents Cu(II)-induced aggregation of Aβ1–40 due to selective Cu(II) 
binding ability in addition to preventing the amyloid fibril formation of Aβ peptides [22]. The 
dissociation constant (KD) for Cu(II) interaction with the chaperon peptide is in the µmol/dm3 
range [22,23].  
Zn is an essential and redox inert trace element. Its role in the neurodegenerative processes is 
not completely evidenced. Reported Zn(II) affinity for Aβ is significantly weaker than, that 
for Cu(II), values of dissociation constants ranging between 1 and 20 µmol/dm3 [21]. 
However, the amyloid aggregates contain relatively high concentration (mmol/dm3) of zinc 
[24]. Several attempts were made to obtain efficient chelators with moderate affinity towards 
the metal ions such as Cu(II), Zn(II) or Fe(III) that participate of the amyloid aggregation, in 
order to prevent the formation of plaques [27]. 
In previous papers [28,36,37,42-44] we reported the evaluation of some 
hydroxypyridinecarboxylic acid derivatives (HPCs) as possible chelating agents for iron (Fe) 
and aluminium (Al(III)). To this aim, the Fe(III) and Al(III) complexes formed by selected 
HPCs were studied. Now we extended these studies also to Cu(II) and Zn(II). On one side, it 
is well known that any Fe(III) and Al(III) chelator can complex also essential metal ions in a 
chelation therapy regiment, thus causing toxic side effects due to metal ion deficiency. For 
example, zinc deficiency problems are sometimes experienced in the deferiprone therapy 
[25,26]. The evaluation of the complexation strength of HPCs towards Cu(II) and Zn(II) can 
allow to predict the extent of essential metal ion removal during the Fe(III) and Al(III) 
chelation therapy. On the other side, the very low cytotoxicity of HPCs and their low 
molecular weight (which can allow the oral activity and the blood brain barrier crossing) can 
represent important advantages also for the employment of HPCs in the AD therapy. 
Therefore, the evaluation of the complexation strength of the HPCs towards Cu(II) and Zn(II) 
can allow to predict if these ligands can remove copper and zinc from Aβ, i.e., if they 
represent good candidates also in the recovery of the disturbed brain metal ion homeostasis on 
AD. 
In the present paper we studied the Cu(II) and Zn(II) binding affinity of two HPCs 
derivatives: 4-hydroxy-5-methyl-3-pyridinecarboxylic acid (DQ5) and 1,5-dimethyl-4-
hydroxy-3-pyridinecarboxylic acid (DQ715) (Scheme 1). Their coordination properties in 
aqueous solution were determined by means of pH-potentiometric titrations, UV-vis and 
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1H NMR or EPR measurements. The effects of DQ715 with Cu(II) chloride were evaluated on 
cell viability of a combined way in human embryonic kidney HEK-293 cells. 
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Scheme 1. 4-hydroxy-5-methyl-3-pyridinecarboxylic acid (DQ5) and 1,5-dimethyl-4-
hydroxy-3-pyridinecarboxylic acid (DQ715) shown in their fully protonated forms (H3L+ and 
H2L+, respectively)  
 
 
 
2. Experimental 
 
 
Chemicals: DQ5 and DQ715 were synthesized as described in Ref [28]. Double-distilled Milli-Q 
water was used for sample preparations. The purity of the ligands was checked and the exact 
concentrations of the stock solutions prepared were determined by potentiometric titrations 
using the program SUPERQUAD for data evaluation [29]. The pH-metric titrations were 
performed with 0.1 mol/dm3 KOH prepared from KOH (Merck). The base was standardised against 
HCl solutions prepared from 36% HCl (Merck). A ZnCl2 stock solution was made by dissolution 
of anhydrous ZnCl2 in a known amount of HCl, and its concentration was determined by 
complexometry via ethylenediaminetetraacetate complexes, and gravimetrically via the 
oxinate. The CuCl2 ion stock solutions were prepared from CuCl2 ·  2H2O (Reanal) dissolved 
in doubly distilled water, and the concentration of the metal ion was determined 
gravimetrically via precipitation of the oxinate.  
 
pH-potentiometric studies: the pH-metric measurements for determining stability constants 
of the proton and metal complexes of the ligands were carried out at an ionic strength of 
0.2 mol/dm3 KCl (Sigma Aldrich) at 25.0 ± 0.1°C in aqueous solution. The titrations were 
performed with a carbonate-free KOH solution of know concentration (ca. 0.1 mol/dm3). In 
order to keep the ionic strength constants KCl has been added to the KOH solution to set the 
K+-concentration 0.2 mol/dm3. The HCl concentrations were determined by potentiometric 
titrations using Gran’s method [30]. An Orion 710A pH-meter equipped with a Metrohm 
6 
 
combined electrode (type 6.0234.1000) and a Metrohm 665 Dosimat burette was used for the 
pH-metric measurements. The electrode system was calibrated according to Irving et al. [34] 
(strong acid vs. strong base; HCl vs. KOH titration) and therefore the pH-meter readings 
could be converted into hydrogen ion concentration. The water ionization constant, pKw 
calculated from strong acid-strong base titrations was 13.76 ± 0.01 under the conditions 
employed. The titrations were performed in the pH range 2 – 11 or until precipitation 
occurred in the samples. The initial volume of the samples was 10 cm3 in case of DQ715 and 
20 cm3 in case of DQ5 related titrations. The ligand concentration was in the range of 
0.5 × 10–3 – 2 × 10–3 mol/dm3, and the metal ion to ligand ratios were 1:1, 1:2 and 1:4. The 
accepted fitting of the titration curves was always less than 0.01 cm3 and the uncertainties 
(3SD values) in the stability constants are given in parentheses in Table 1. The samples were 
in all cases deoxygenated by bubbling purified argon for ca. 10 min before the measurements, 
and argon was also passed across the solutions during the titrations.  
The protonation constants of the ligands were determined with the computer program 
SUPERQUAD [29]. PSEQUAD [31] was utilized to establish the stoichiometry of the 
complexes and to calculate their stability constants (logβ (MpLqHr). β (MpLqHr) is defined for 
the general equilibrium reaction pM + qL + rH MpLqHr as β (MpLqHr) = 
[MpLqHr]/[M]p[L]q[H]r, where M denotes the metal ion, L is the completely deprotonated 
ligand molecule, and p, q and r are the number of metal, ligand, and proton atoms, 
respectively. According to the calibration protocol employed, the protonation and stability 
constants are concentration constants which refer to the given ionic strenght. The calculations 
were always made from the experimental titration data measured in the absence of any 
precipitate in the solution. 
 
Spectrophotometric measurements: UV-Vis spectrophotometric measurements were 
performed in aqueous solution at 25.0 ± 0.1 oC on solutions containing the ligand (either 
DQ715 or DQ5) at a 8.0 × 10–5 mol/dm3 concentration, and the metal (either Cu(II) or Zn(II)) 
at the following metal to ligands ratios: 0:1, 1:4, 1:2, 1:1. The pH range was from 2 to 11, and 
the ionic strength was 0.20 mol/dm3 (KCl). The spectra were recorded under argon 
atmosphere. A Hewlett Packard 8452A diode array spectrophotometer was used to record the 
UV-vis spectra in the interval 290 – 820 nm. The pathlength was 1 cm using quartz cuvettes. 
Protonation and stability constants and the individual spectra of the species were calculated by 
the computer program PSEQUAD [31]. 
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1H NMR measurements: 1H NMR studies were carried out on a Bruker Ultrashield 500 Plus 
instrument equipped with a 5 mm capillary NMR tube. In the NMR measurements the 
magnetic field was stabilised by locking with the 2D signal of the solvent. The sample 
temperature was set to 25 ± 1 °C during all data acquisitions. Chemical shifts are reported in 
ppm (δH) from 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) as internal reference. The 
1H NMR measurements were performed with a WATERGATE solvent suppression scheme. 
All samples were measured with the same experimental parameters, the same spectrometer 
and the same probe. The relaxation delay, the delay for binomial water suppression, and the 
number of scans, were respectively 2 s, 150 µs, and 64. Spectra were collected for DQ5 and 
DQ715 ligands  and for Zn(II) – DQ715 system in 90:10 H2O/D2O mixtures at 1.1 mmol/dm3 
(DQ5) and 2 mmol/dm3 (DQ715) ligand concentration. The Zn(II) – DQ715 ratios were 0:1, 
1:1, 1:2 and 1:4. The ionic strength was adjusted to I = 0.2 mol/dm3 with KCl in each sample. 
The pH of the solutions (pHobserved) was measured with a pH-sensitive glass electrode 
(Metrohm 6.0234.100) and an Orion 710A pH meter, calibrated according to the procedure 
described in the literature [34]). The equilibrium constants and the limiting chemical shifts of 
the species formed during protonation and Zn(II)-complexation were calculated by 
PSEQUAD [31]. 
 
EPR measurements: All CW-EPR spectra were recorded with a BRUKER EleXsys E500 
spectrometer (microwave frequency ~9.7 GHz, microwave power 13 mW, modulation 
amplitude 5 G, modulation frequency 100 kHz). The isotropic EPR spectra were recorded at 
room temperature in a circulating system during a titration. Nine EPR spectra were recorded 
at 1 mmol/dm3 CuCl2 and 2 mmol/dm3 DQ715 ligand concentration, and six at 2 mmol/dm3 
CuCl2 and 2 mmol/dm3 DQ715 ligand concentration, in the pH range 2 – 6 and 2 – 8.5, 
respectively. At higher pH values precipitation was detected in both cases. The ionic strength 
of 0.2 mol/dm3 were adjusted with KCl. KOH solution was added to the stock solution to 
change the pH which was measured with an Orion 710A pH-meter equipped with a Metrohm 
6.0234.100 glass elecrode. A Heidolph Pumpdrive 5101 peristaltic pump was used to circulate 
the solution from the titration pot through a capillary tube into the cavity of the instrument. 
The titrations were carried out under nitrogen atmosphere. At various pH values, samples of 
0.1 cm3 were taken, and frozen in liquid nitrogen, and the CW-EPR spectra were recorded 
under the same instrumental conditions as the room-temperature spectra described above.  
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Evaluation of EPR spectra: The series of room-temperature EPR spectra were simulated 
simultaneously by the „two-dimensional” method using the 2D_EPR program [32]. Each 
component curve was described by the isotropic EPR parameters go, AoCu copper hyperfine 
coupling, and the relaxation parameters α, β, γ which define the linewidth through the 
equation σMI = α + β MI + γ MI2, where MI denotes the magnetic quantum number of copper 
nucleus. The concentrations of the complexes were varied by fitting their formation constants, 
β(MpLqHr) defined above, in the experimental description of pH-potentiometric studies. 
The anisotropic spectra were analysed individually by the EPR program [33], which 
gives the anisotropic EPR parameters (gx, gy, gz, AxCu, AyCu, AzCu) and the orientation dependent 
linewidth parameters).  
For each spectrum, the noise-corrected regression parameter (R) is derived from the 
average square deviation (SQD) between the experimental and the calculated intensities. For 
the series of spectra, the fit is characterized by the overall regression coefficient R, calculated 
from the overall average SQD. The details of the statistical analysis were published 
previously [32]. Since a natural CuCl2 was used for the measurements, all spectra were 
calculated as the sum of the spectra of 63Cu and 65Cu weighted by their natural abundances. 
The copper coupling constants and the relaxation parameters were obtained in field units 
(Gauss = 10–4 T). 
 
Cell cultures and Cytotoxicity Assay Human Embryonic Kidney 293 (HEK-293) cell line 
was obtained by ATCC, Rockville, MD. Cells were maintained in the logarithmic phase at 
37 °C in a 5 % carbon dioxide atmosphere using the D-MEM medium (Euroclone) containing 
10 % fetal calf serum (Euroclone, Milan, Italy), antibiotics (50 units·cm-3 penicillin and 
50 µg·cm–3 streptomycin) and 2 mmol/dm3 L-glutamine. The growth inhibitory effect toward 
HEK-293 cell line was evaluated by means of MTT (tetrazolium salt reduction) assay [35]. 
Briefly, 3·103 cells were seeded in 96-well microplates in growth medium (0.1 cm3) and then 
incubated at 37 °C in a 5% carbon dioxide atmosphere. After 24 h, cells were treated with the 
compound to be studied at the appropriate concentration. Triplicate cultures were established 
for each treatment. After 24 h, each well was treated with 0.01 cm3of a 5 mg cm–3 MTT saline 
solution, and after following 5 h of incubation, 0.1 cm3 of a sodium dodecylsulfate (SDS) 
solution in HCl (0.01 mol/dm3) were added. After overnight incubation in the dark at 37 °C in 
a 5 % carbon dioxide atmosphere, the inhibition of cell growth induced by tested compounds 
was detected by measuring the absorbance of each well at 570 nm using a Bio-Rad 680 
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microplate reader (Milan, Italy). Mean absorbance for each drug dose was expressed as a 
percentage of the control untreated well absorbance and plotted vs. drug concentration. IC50 
values represent the drug concentrations that reduced the mean absorbance at 570 nm to 50 % 
of those in the untreated control wells. 
 
 
3. Results and discussion 
 
 
3.1. Protonation constants 
 
The acid-base properties of DQ5 and DQ715 were studied by potentiometric and 
spectroscopic techniques. The protonation constants presented here for these ligands are in 
good agreement with those reported in previous papers, when the difference in ionic strength 
is taken into account [28]. The pKa values also corresponds to those of related compounds 
with different ring substituents [28,36,37,38]. 
The protonation constants of DQ715, and DQ5 are listed in Table 1. The significant decreases 
in acidity of the carboxylic group in the ligands (log K(COO−) ≤ 1) can be mainly attributed 
to the formation of an intramolecular hydrogen-bonding between the COO− and the phenolic 
OH, which favours the liberation of the first proton [28]. The significantly lower second pKa 
in DQ715 than the pKa of the phenolic OH in phenol molecule or in salicylic acid has 
presumably due to the possibility of the formation of a chinoid isomeric structure (Scheme 2). 
The existence of the chinoidic and aromatic isomer forms of L– is supported by 1H NMR 
measurements (Fig. 1.a.).  
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Scheme 2. Deprotonation steps of DQ5 and DQ715 
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Fig. 1. Low-field region of the 1H NMR spectra of the ligands at the indicated pH values at T 
= 298 K (a, b) and T = 280 K (c) (cDQ5 = 1.1 × 10–3 mol/dm3, cDQ715 = 2 × 10–3 mol/dm3 
I = 0.2 mol/dm3(KCl)) 
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The exclusive formation of HL is seen at pH 2.11 and 4.50. Increasing the pH the signals start 
to broaden and shifted. The shifting can be explained by the deprotonation processes and the 
broadening may support the assumption that two tautomeric forms exist at these pH values. 
The chinoidic and the aromatic forms are in a fast exchange with respect to the 1H NMR time 
scale resulting in the broadened signals, however, at pH 10.35 the peaks become sharp again 
suggesting that a single species, the aromatic form is dominating again at this high pH. 
An unequivocal assignment of the pK2 and pK3 values of DQ5 is not possible either, because 
4-hydroxypyridine derivatives can adopt a chinoid electronic configuration in tautomeric 
equilibrium with the corresponding aromatic form. In case of DQ5 three HL- forms can exist 
(Scheme 2.). The similar behavior could also be seen in the spectra (Fig. 1.b). The signals 
start to broaden and shift above pH ~ 5.4, and they practically disappear at 9.37. Probably at 
this pH value the three different forms exist simultaneously also in fast exchange. Increasing 
the pH the signals become sharp again. At pH 9.37 1H NMR spectrum was recorded at 280 K 
(Fig. 1.c) too showing that one of the signals (δ = 8.45 ppm) separated and became sharper 
while the signals of the other two isomers remained broad. This spectrum may also support 
the coexistence of three forms in the pH range 6.0 – 9.7. 
 
 
The last pKa of DQ5 could not be accurately measured because it is too high. Therefore, we 
disregarded the last proton dissociation process and considered HL as the complex-forming 
species in the equilibrium pM + qHL + rH = MpLqHr+q (for simplicity, charges will be 
generally omitted from the formulae, except in the Tables). In this way, more accurate 
formation constants were obtained, although their numerical values differ by the value of the 
last pKa from those calculated in the usual way for the equilibrium pM + qL + rH = MpLqHr. 
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Table 1. pKa values of DQ5 and DQ715, and stability constants of Cu(II) and Zn(II) 
complexes at 298 K in aqueous I = 0.2 mol/dm3(KCl) 
 
DQ5 DQ715 
species pKa / log β species pKa / log β 
 pH-pot UV-vis  pH-pot UV-vis 1H NMR 
H3L+  0.23(6)* H2L+  0.40(1)*  
H2L 6.60(1) 6.61(2) HL 6.64(1) 6.63(1) 6.66(1) 
HL– > 11  
 pH-pot UV-vis  pH-pot UV-vis EPR 
Cu(HL)+ 6.24(1) 6.39(3) CuL+ 6.27(1) 6.41(2) 6.47(2) 
Cu(HL)2 11.33(5) 11.33(9) CuL2 10.95(2) 10.97(5) 11.02(2) 
KD 3.1 × 10−7 mol/dm3 5.1 × 10−7 mol/dm3 
 pH -pot  pH-pot 1H NMR 
Zn(HL)+ 3.75(2) ZnL+ 3.77(2) 3.79(3) 
Zn(HL)2 6.9(1) ZnL2 7.06(3) 6.96(7) 
KD 7.5 × 10−4 mol/dm3 8.2 × 10−4 mol/dm3 
KD =[M]free Σ[HxL]/Σ[MpHqLr] computed at pH 7.4 for cM = 2.5 ×10−5 mol/dm3, 
cL = 5.0 × 10−5 mol/dm3 
* Data are taken from Ref [28] 
 
 
3.2. Cu(II) – DQ5 and Cu(II) – DQ715 systems 
 
The chelating ability of DQ5 and DQ715 for Cu(II) was evaluated on the basis of the 
cumulative formation constants of their complexes, which were determined by potentiometric, 
UV-vis, and (in case of DQ715) by EPR measurements. 
The pH-potentiometric titration curves measured at 1:1, 1:2 and 1:4 metal ion-to-ligand 
concentration ratios, normalized to the ligand concentration, are depicted in Fig. 2. (In all 
cases, strong acid was added to the solution before titration in order to ensure acidic 
conditions at the beginning of the measurement. The amount of potassium hydroxide 
consumed by the strong acid has been subtracted from the total OH− consumption in Fig. 2.) 
The predominant species for both ligands are mono and bis comlexes. No other species could 
be assumed to improve the fit of the titration curves; e.g. no tris complex formation in 
measurable concentration could be indication under the experimental conditions. 
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The shape of the analogous titration curves in both Cu(II)–ligand systems are similar until pH 
5, indicating similar processes in the solution. Significant differences between DQ5 and 
DQ715 are evident in slightly acidic and neutral solutions. Complex formation starts at 
pH > 3. After a proton loss at the carboxylic group, in the presence of the metal ion one 
deprotonation step is observed on the titration curves. Although potentiometric data do not 
give any structural information, it is reasonable that in all complexes the ligands coordinate to 
the metal ion through the carboxylate oxygen and phenolate (bidentate chelation), and the 
pyridine-N remains protonated in the Cu–DQ5 complexes in the pH range studied. This result 
is similar to those obtained for the complexes formed by 3-hydroxy-2-pyridinecarboxylic acid 
and 4-hydroxy-3-pyridinecarboxylic acid with aluminium(III) and iron(III) where the 
pyridine-N remains protonated in the complex at neutral pH [42].  
 
The sharp break on the titration curve at ligand excess indicates that precipitation occurs at 
pH ≈ 5 in the Cu(II)–DQ5 solutions. Although the precipitate was not accurately analysed, 
presumably it is the neutral bis complex CuL2, as when the complex as filtered off and 
redissolved in dilute HCl acid, significant amount of the ligand could be detected 
spectrophotometrically. It should also be mentioned that in the samples with ligand excess 
precipitation started at the same metal ion concentration when the concentration of CuL2 (as 
calculated from the stability constants listed in Table 1.) reached the value of about 2.7 × 10−4 
mol/dm3.  
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b. Cu(II)–DQ715  
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Fig. 2. Left: pH-potentiometric titration curves with the fitted curves (with continuous line) 
for ligands and for the copper(II)–ligands systems at different metal-to-ligand concentration 
ratios. Right: distribution diagrams of the most important Cu(II) species in the presence of: 
(a) DQ5; cCu(II) = 5 × 10–4 mol/dm3, cDQ5 = 1 × 10–3 mol/dm3 
(b) DQ715; cCu(II) = 1 × 10–3 mol/dm3, cDQ715 = 2 × 10–3 mol/dm3 
(I = 0.2 mol/dm3 (KCl), T = 298 K) 
 
Note that in the case of DQ5 the monoprotonated species while in the case of DQ715 the fully 
deprotonated catecholic L is the complex forming ligand form. 
The limited solubility of the ligands in water allowed to carry out the pH-potentiometric 
titrations at a maximum of ∼2 mmol×dm–3 DQ715 and ∼1 mmol×dm–3 DQ5 concentrations, 
and despite the low solubility of DQ5 bis complex, interpretation of the potentiometric data 
leaves little doubt on the speciation model. We performed UV-vis spectrophotometric 
measurements to confirm the pH-potentiometric speciation result.  Absorbance curves of the 
Cu(II)-DQ715 system are shown in Fig. 3.  
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Fig. 3. Spectrophotometric absorbance curves of the Cu(II)–DQ715 system at various pH 
values; cCu(II) = 4 × 10–5 mol/dm3, cDQ715 = 8 × 10–5 mol/dm3. The inset shows the change in 
the absorbance the fitted curves were calculated (with dashed line) at 268 nm as function of 
the pH (I = 0.2 mol/dm3 (KCl), T = 298 K) 
 
 
Fig. 3. shows the pH-dependent UV-vis spectra of Cu(II)–DQ715 system and the change in 
the absorbance at 264 nm as function of the pH at various metal-to-ligand ratios. Spectra are 
very similar to those obtained for Cu(II)–DQ5 system (not shown). For DQ715 at pH 2, the 
main peak at 252 nm is due to π → π∗ transition of the pyridinic ring, and by increasing the 
pH the deprotonation causes a bathochromic shift till around 270 nm. The presence of Cu(II) 
does not modify strongly the UV-vis spectra of the ligands. Only small modifications in the 
intensity and in the wavelength occur as a function of the pH. The complex formation was 
evidenced by monitoring of the absorption change in the wavelength range 230 – 350 nm.  At 
in this low concentration no other absorption band disturbed the detected spectra. The stability 
constants of the different complexes/species were determined from the pH-dependent spectra. 
For both ligands, the UV-vis spectra allowed the detection of two complexes, CuL and CuL2 
for DQ715, and CuLH and CuL2H2 for DQ5 and the calculation of their stability constants. 
The UV-vis log β values agree well with those determined by potentiometrically (see Table 
1), thus confirming the formation of any other species in these metal-ligand systems. 
EPR measurements were also carried out for Cu(II)–DQ715 solutions in order to obtain 
structural information on the complexes. The isotropic and anisotropic EPR spectra could be 
explained by taking into account the formation of CuL and CuL2 complexes, beside the 
copper(II)aqua complex (Fig. 4). The slight decrease of the g values in CuL comparing with 
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the g values of the aqua complex indicates metal ion coordination by weak oxygen donors 
[COO–,O–]. Further decrease in g and increase in A values occur in CuL2 indicating 
2 × [COO–,O–]coordination. The coordination of the two ligands in cis-trans geometric 
isomers could not be distinguished, possibly because of their very close EPR parameters. 
Determination of both isotropic and anisotropic EPR data of complexes CuL and CuL2 
allowed to predict the sign of their anisotropic copper hyperfine couplings (Ax and Ay) (The 
determination of signs otherwise is a difficult problem and requires ENDOR or pulsed EPR 
measurements. The positive or negative sign of these two values can change easily because of 
the similar magnitudes but varying signs of the contributed Fermi contact term, spin-dipolar 
coupling and the spin-orbit interaction). In this study the measured isotropic hyperfine values 
have been compared with those of the averaged values calculated by the equation Ao = (Ax + 
Ay + Az)/3 using different signs for Ax and Ay. (Negative sign for Az is known for copper(II) 
complexes with elongated octahedral geometry). The signs giving the best accordance are 
shown in Table 2. The good agreement between the measured and calculated values presume 
also that the complex structure formed in solution is kept upon freezing. Comparing the EPR 
parameters of CuL (go = 2.166 and Ao = 53 G) with those of copper(II)-fluorosalicylic acid 
analogoues (go =  ~ 2.179 – 2.186 and Ao = ~ 35 – 38 G)   [41], we can conclude that much 
higher go values and lower Ao values could be detected than for the different fluorosalicylic 
complexes. This indicates a significantly higher ligand field for DQ715 as compared to 
fluorosalicylic acid, owing to the positive inductive effect of the pyridinic nitrogen in contrast 
with the negative inductive effect of the fluorine. This agrees with the higher formation 
constants and the predominant formation of CuL in case of DQ715.  
The formation constants and EPR parameters for the various Cu(II) complexes are 
summarized in Tables 1 and 2. 
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Fig. 4. (a) pH dependent series of experimental (black) and simulated (gray) EPR spectra 
(cDQ715 = 2 × 10–3 mol/dm3, cCu = 1 × 10–3 mol/dm3, I = 0.2 mol/dm3 (KCl) T = 298 K), and 
(b) calculated component EPR spectra obtained by the „two-dimensional” simulation 
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Table 2. EPR parameters of components formed in Cu(II) –DQ715 system 
 
Isotropic EPR 
dataa 
Anisotropic EPR datab Calculated isotropic 
EPR data 
 
go │Ao│ 
/G 
g┴ 
gx,gy 
gǁǁ 
gz 
A┴/G 
Ax, Ay /Gc 
Aǁǁ/G 
Az / G 
go,calc │Ao,calc│d 
/G 
Cu2+ 2.194(1) 34.6(6) 2.079 2.412 8.0 –116.0 2.190 37.5 
CuL 2.166 (1) 53.1(1) 2.069, 2.069 2.347 12.0, 
–12.0 –147.0 2.161 53.2 
CuL2 2.149 (1) 60.8(1) 2.066, 2.059 2.329 –8.1,  
–15.9 –150.4 2.151 62.0 
aUncertainties (standard deviations) of the last digits are shown in parentheses. For the proton 
complexes the pH-potentiometric formation constants logβ(LH2) = 7.66 and logβ(LH) = 6.66 
were used in the EPR analysis. 
bThe experimental errors were ± 0.001 for gx and gy and ± 0.0005 for gz, ± 2 G for Ax and Ay 
and ± 1 G for Az.  
cThe signs of the experimental values were derived from a comparison of Ao,calc with the 
experimental Ao. d│Ao,calc│ = │(Ax + Ay + Az) / 3│ 
 
3.3. Zn(II) – DQ5 and Zn(II) – DQ715 systems 
 
The complex formation constants of Zn(II)–DQ715 and Zn(II)–DQ5 systems are listed in 
Table 1. Both systems comprise a small number of mononuclear complexes. The order of 
magnitude of the complex stability in this study are similar with the earlier findings in the 
Zn(II)–2-hydroxynicotinic acid system [44]. This suggests the same binding mode in these 
complexes, i.e. a bidentate coordination of the carboxylate and hydroxyl groups. Accordingly, 
the pyridine-N remains protonated in the complexes. Representative species-distribution 
diagrams for typical Zn(II)–DQ715 and Zn(II)–DQ5 solutions are shown in Fig. 5. The metal 
complex speciation in these systems do not differ considerably from each other. It can be seen 
that the complexation begins at pH 3.5 due to the formation of the monocomplex. The bis 
complex becomes predominant above pH 6. No evidence was found for the presence of any 
tris-complex. For both Zn(II)–DQ715 and Zn(II)–DQ5 systems, the pH interval which could 
be examined in potentiometric and 1H NMR measurements was limited because of the early 
precipitation of solid compounds. The pH at which the precipitation occurs (pH ≈ 8) and the 
appearance of the precipitate suggest that it is Zn(OH)2.  
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Fig. 5. Distribution diagrams of the most important Zn(II) species in the presence of  
(a) DQ5; cZn(II) = 5 × 10–4 mol/dm3, cDQ5 = 1 × 10–3 mol/dm3 
(b) DQ715; cZn(II) = 1 × 10–3, cDQ715 = 2 × 10–3 mol/dm3 
(I = 0.2 mol/dm3 (KCl) T = 298 K) 
 
To support the potentiometric data, 1H NMR spectra were collected in the presence of DQ715 
at various pH values in H2O/D2O solution at 1:0, 1:1, 1:2, and 1:4 metal-to-ligand ratios. Due 
to the formation of the kinetically labile Zn(II) complexes, the position but not the number 
and multiplicity of the NMR signals, change as a function of pH. Stability constants of the 
complexes were calculated from the extent of shifts of the signals by PSEQUAD. Results are 
very similar to those obtained from the pH-potentiometry (Table 1). Fig. 6. shows the 
measured and calculated shifts of the N-CH-C-COO depending on the pH. 
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Fig. 6. Calculated and experimental 1H NMR shifts of the of N-CH-C-COO hydrogen of 
DQ715 as a function of the pH in Zn(II)–DQ715 system (cDQ715 = 2 × 10–3 mol/dm3 I = 0.2 M 
(KCl) T = 298 K) 
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The Zn(II)–ligand complex formation was monitored by UV-vis spectrophotometric 
measurements too, but suitable UV-vis spectra could not be obtained because of the slight 
changes in the absorption due to the low level of complexes formation with both DQ5 and 
DQ715.  
 
3.4. Cytotoxicity studies 
 
HEK-293 human embryonic kidney cells were tested for their sensitivity to Cu(II) (as CuCl2)-
chloride and DQ715. Cells were treated for 24 h with increasing concentrations of CuCl2 and 
DQ715, and cell viability was determined using the MTT test. Results are reported in Fig. 7.  
As previously described [28], DQ715 proved to be hardly effective in decreasing cell 
viability, with an IC50 value of 1.4 mmol×dm3. Conversely, IC50 calculated with CuCl2 was 
0.15 mmol×dm3. 
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Fig. 7. Cytotoxicity profile of CuCl2 and DQ715. HEK-293 cells were treated for 24 h with 
increasing concentrations of CuCl2 (●) or DQ715 (○). Cytotoxicity was evaluated by the MTT 
test. IC50 values were calculated by four parameter logistic model (P < 0.05). Values are 
shown as the means (±SD) of five independent experiments. 
 
 
In order to study the effect of DQ715 in Cu(II) overload, HEK-293 cells were pre-treated with 
0.15 mmol/dm3 CuCl2 for 24 h and further challenged with increasing concentrations (0.0 –
 0.7 mmol/dm3) of DQ715 for additional 24 h treatment. Fig. 8 shows the results obtained 
with MTT test. Co-treatment of HEK-293 cell with DQ715 and CuCl2 determined a DQ715 
dose-dependent decrease of copper salt cytotoxicity, supporting the hypothesis that DQ715 
can reduce the cupper induced antiproliferative effect. 
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Fig. 8. Effect of Cu(II) and DQ715 combined treatment. HEK-293 cells were treated for 24 h 
with 0.15 mmol/dm3 of CuCl2 and then washed twice with PBS, and re-incubated with fresh 
complete medium (black) or medium added with increasing concentration of DQ715 (white), 
for further 24 h before MTT determination. Values are shown as the means (±SD) of five 
independent  experiments. 
 
4. Conclusions 
 
The chemical interactions between the metals Zn(II) and Cu(II) and the ligands DQ715 and 
DQ5 have been investigated. The speciations are very similar, as only mononuclear mono and 
bis complexes are detected in solution. The two ligands have a similar metal binding ability 
towards Zn(II) and Cu(II). They are typical hard ligands and therefore form weaker Zn(II) and 
Cu(II) complexes than Fe(III) and Al(III) [28]. DQ715 forms slightly weaker complexes than 
DQ5 due to the N-methyl substitution of the pyridine ring which increases the hard character 
of the chelator. To compare the metal binding strength of the ligands at physiological pH, the 
KD values have been calculated for the complexes at pH 7.4. Values obtained are shown in 
Table 1. The order of magnitude of the KD value of the Zn(II) complexes is mmol/dm3, that 
means that Zn(II) binding affinity of both ligands is very low. Therefore the ligands do not 
have any effect on the zinc homeostasis in vivo, i.e. DQ5 and DQ715 are expected to remove 
only a small amount of zinc. This low affinity may be important if DQ5 and DQ715 are used 
as Fe or Al chelators, because zinc deficiency problems are sometimes experienced in hard 
metal chelation therapy (e.g. for deferiprone [25,26]). DQ5 and DQ715 are expected to cause 
no zinc deficiency problem.  
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The affinity of the ligands for Cu(II) is higher than for Zn(II). The KD values are several tenth 
of micromolar for both ligands. The KD values reported in the literature for Cu(Aβ) range 
from 10 pM to 100 nM [21]. In any case it appears that DQ5 and DQ715 cannot retrieve 
Cu(II) from the amyloid-aggregates. However, the strength of the interactions with Cu(II) can 
be enough to bind the copper excess in the cells and protect them from the copper-induced 
redox processes, which would generate ROS species. This protection might explain why the 
Cu(II)-treated cells showed higher viability in the presence of DQ715. This protecting effect 
has been evaluated also in the presence of Fe(III), and in that case it was attributed to the 
metal chelation [28]. The acute and chronic Cu(II) toxicity can result in Cu(II)-induced 
oxidative damage that has been implicated in disorders associated with abnormal copper 
metabolism, liver disease and severe neurological defects. Therefore, although the ligand is 
not a suitable chelator for Cu(II) and cannot remove this ion from the beta-amyloid proteins, it 
appears suitable to protect the cells from the Fe(III) and Cu(II) related oxidative stress, which 
may be involved in neurodegenerative disorders, like Alzheimer’s disease. 
 
Acknowledgements 
 
This work was supported by the Hungarian Research Fund (OTKA K77833), and TÁMOP-
4.2.2.A-11/1/KONV-2012-0052, supported by the European Union, and it was co-financed by 
the European Regional Fund and by the Italian-Hungarian CNR-HAS Bilateral Research 
Program “Venzo-Kiss”. This research was realized in the frames of TÁMOP 4.2.4. A/2-11-1-
2012-0001 „National Excellence Program – Elaborating and operating an inland student and 
researcher personal support system” The project was subsidized by the European Union and 
co-financed by the European Social Fund. T. Jakusch gratefully acknowledges the financial 
support of J. Bolyai research fellowship. 
 
 
References 
 
 
[1] F.P. Guengerich, J. Biol. Chem., 284 (2009) 18557. 
 
[2] I. Bertini, G. Cavallaro, J. Biol. Inorg. Chem., 13 (2008), 3. 
 
[3] M. Arredondo, M.T. Núñez, Mol. Aspects Med., 26 (2005), 313. 
 
[4] C. Fraga, Mol. Aspects Med., 26 (2005) 235. 
 
24 
 
[5] N. Arnal, M.J. Tacconi de Alaniz, C.A. Marra, Biochim. Biophys. Acta, 1820  (2012) 931. 
 
[6] D.E. Carter, Environ. Health Perspect., 103 (1995) 17. 
[7] K.T. Suzuki, T. Maitani, Biochem. J., 199 (1981) 289. 
[8] E.D. Harris, Crit. Rev. Clin. Lab. Sci., 40 (2003) 547. 
 
[9] C.L. Keen, L.A. Hanna, L. Lanoue, J.Y. Uriu-Adams, R.B. Rucker, M.S. Clegg, J. Nutr., 
133 (2003) 1477S. 
 
[10] J.T. Saari, Can. J. Physiol. Pharmacol., 78 (2000) 848. 
 
[11] C. Vulpe, B. Levinson, S. Whitney, S. Packman, J. Gitschier, Nat. Genet., 3 (1993) 7. 
 
[12] P.C. Bull, G.R. Thomas, J.M. Rommens, J.R. Forbes, D.W. Cox, Nat. Genet., 5 (1995) 
327. 
 
[13] E. Gaggelli, H. Kozłowski, D. Valensin, G. Valensin, Chem. Rev., 106 (2006) 1995 
1995. 
 
[14] A Schmuck, A.M Roussel, J Arnaud, V Ducros, A Favier, A Franco, J. Am. Coll. Nutr., 
15 (1996) 462. 
 
[15] A. Mezzetti, S.D. Pierdomenico, F. Costantini, F. Romano, D. De Cesare, F. Cuccurullo, 
T. Imbastaro, G. Riario-Sforza, F. Di Giacomo, G. Zuliani, R. Fellin Free Radical Biol. Med.,  
25 (1998) 676. 
 
[16] G. J. Brewer, J. Trace Elem. Med. Bio., 26, (2012) 89. 
 
[17] A.R. White, G. Multhaup, D. Galatis, W.J. McKinstry, M.W. Parker, R. Pipkorn, K. 
Beyreuther, C.L. Masters, R. Cappai, J. Neurosci., 22 (2002) 365. 
 
[18] P.M. Doraiswamy, A.E. Finefrock, Lancet Neurol., 3 (2004) 431. 
[19] J. Lu, D.M. Wu, Y.L. Zheng, D.X. Sun, B. Hu, Q. Shan, Z.F. Zhang, S.H. Fan, Brain, 
Behavior, and Immunity, 23 (2009) 193. 
[20] R.A Cherny, J.T Legg, C.A McLean, D Fairlie, X Huang, C.S Atwood, K Beyreuther, 
R.E Tanzi, C.L Masters, A.I Bush, J. Biol. Chem., 274 (1999) 23223. 
[21] P. Faller and C. Hureau, Dalton Trans., (2009) 1080. 
[22] M.F. Ahmad, D. Singh, A. Taiyab, T. Ramakrishna, B. Raman, C.M. Rao, J. Mol. Biol., 
382 (2008) 812. 
[23] M. Raju, P. Santhoshkumar, T.M. Henzl, K.K. Sharma, Free Radical Biol. Med., 50 
(2011) 1429. 
25 
 
[24] M.A. Lovell, J.D. Robertson, W.J. Teesdale, J.L. Campbell and W. R., Markesbery, J. 
Neurol. Sci., 158 (1998) 47. 
 
[25] G.J. Kontoghiorghes, Toxicol. Lett. 80 (1995) 1. 
 
[26] G.J. Kontoghiorghes, M.B. Agarwal, R.W. Grady, A. Koinagou,, J.J. Marx, Lancet 356 
(2000) 428. 
 
[27] H. Kozlowski, M. Luczkowski, M. Remelli, D. Valensin, Coord. Chem. Rev., 256 (2012) 
2129. 
 
[28] A. Dean, É. Sija, É. Zsigó, M. G. Ferlin, D. Marton, V. Gandin, C. Marzano, P.Pastore, 
D. Badocco, A. Venzoe, R. Bertani, T. Kiss, V. Di Marco, Eur. J. Inorg. Chem. 8 (2013) 
1310-. 
 
[29] P. Gans, A. Sabatini and A. Vacca, J. Chem. Soc., Dalton Trans., (1985) 1195. 
[30] G. Gran, ActaChem. Scand., 4 (1950) 559. 
[31] L. Zékány, I. Nagypál, D.L. Leggett (Ed.), Plenum Press, New York, 1985, 291. 
[32] A. Rockenbauer, T. Szabó-Plánka, Zs. Árkosi, L. Korecz, J. Am. Chem. Soc. 123 (2001) 
7646. 
 
[33] A. Rockenbauer, L. Korecz, Appl. Magn. Reson. 10 (1996) 29. 
 
[34] H.M. Irving, M.G. Miles, L.D. Petit, Anal. Chim. Acta, 38 (1967) 475. 
[35] M.C. Alley, D.A. Scudiero, A. Monks, M.L. Hursey, M.J. Czerwinski, D.L. Fine, B.J. 
Abbott, J.G. Mayo, R.H. Shoemaker, M.R. Boyd, Cancer Res. 48 (1988) 589. 
[36] E. Sija, A. Dean, T. Jakusch, V.B. Di Marco, A. Venzo, T. Kiss, Monatsh. Chem., 142 
(2011) 399. 
 
[37] A. Dean, M.G. Ferlin, P. Brun, I. Castagliuolo, R.A. Yokel, A. Venzo, G.G Bombi, V.B. 
Di Marco, Inorg. Chim. Acta, 373 (2011) 179. 
 
[38] V.B. Di Marco, A. Dean, R.A. Yokel, H. Li, G.G. Bombi, Polyhedron, 26 (2007) 3227. 
[39] A.E. Martell, R.M. Smith, Critical Stability Constants, Plenum, New York, vol. 2, 1975. 
 
[40] M. Jezowska-Bojczuk, H. Kozlowski, A. Zubor, T. Kiss, M. Branca, G. Micera, A. 
Dessı ̀, J. Chem. Soc., Dalton Trans. (1990) 2903. 
 
[41] T. Szabó-Plánka, B. Gyurcsik, I. Pálinkó, N. V. Nagy, A. Rockenbauer, R. Šípoš, J. 
Šima, M. Melník, J. Inorg. Biochem 105 (2011) 75. 
 
[42] V.B. Di Marco, R.A. Yokel, M.G. Ferlin, A. Tapparo, G.G. Bombi, Eur. J. Inorg. Chem. 
(2002) 2648. 
 
[43] V.B. Di Marco, A. Tapparo, G.G. Bombi, Ann. Chim. (Rome), 89 (1999) 535. 
 
26 
 
[44] V.B. Di Marco, A.Tapparo, A. Dolmella, G.G. Bombi; Inorg.Chim. Acta 357 (2004) 135. 
 
 
27 
 
Table 1. pKa values of DQ5 and DQ715, and stability constants of Cu(II) and Zn(II) 
complexes at 298 K in aqueous I =  0.2 mol/dm3 (KCl) 
 
DQ5 DQ715 
species pKa / log β species pKa / log β 
 pH-pot UV-vis  pH-pot UV-vis 1H NMR 
H3L+  0.23(6)* H2L+  0.40(1)*  
H2L 6.60(1) 6.61(2) HL 6.64(1) 6.63(1) 6.66(1) 
HL– > 11  
 pH-pot UV-vis  pH-pot UV-vis EPR 
Cu(HL)+ 6.24(1) 6.39(3) CuL+ 6.27(1) 6.41(2) 6.47(2) 
Cu(HL)2 11.33(5) 11.33(9) CuL2 10.95(2) 10.97(5) 11.02(2) 
KD 3.1 × 10−7 mol/dm3 5.1 × 10−7 mol/dm3 
 pH -pot  pH-pot 1H NMR 
Zn(HL)+ 3.75(2) ZnL+ 3.77(2) 3.79(3) 
Zn(HL)2 6.9(1) ZnL2 7.06(3) 6.96(7) 
KD 7.5 × 10−4 mol/dm3 8.2 × 10−4 mol/dm3 
KD =[M]free Σ[HxL]/Σ[MpHqLr] computed at pH 7.4 for cM = 2.5 ×10−5 mol/dm3, 
cL = 5.0 × 10−5 mol/dm3 
* Data are taken from Ref [28] 
 
Table 2. EPR parameters of components formed in Cu(II) –DQ715 system 
 
Isotropic EPR 
dataa 
Anisotropic EPR datab Calculated isotropic 
EPR data 
 
go │Ao│ 
/G 
g┴ 
gx,gy 
gǁǁ 
gz 
A┴/G 
Ax, Ay /Gc 
Aǁǁ/G 
Az / G 
go,calc │Ao,calc│d 
/G 
Cu2+ 2.194(1) 34.6(6) 2.079 2.412 8.0 -116.0 2.190 37.5 
CuL 2.166 (1) 53.1(1) 2.069, 2.069 2.347 12.0, 
-12.0 -147.0 2.161 53.2 
CuL2 2.149 (1) 60.8(1) 2.066, 2.059 2.329 -8.1,  
-15.9 -150.4 2.151 62.0 
aUncertainties (standard deviations) of the last digits are shown in parentheses. For the proton complexes the pH-
potentiometric formation constants logβ(LH2) = 7.66 and logβ(LH) = 6.66 were used in the EPR analysis. 
bThe experimental errors were ± 0.001 for gx and gy and ± 0.0005 for gz, ± 2 G for Ax and Ay and ± 1 G for Az.  
cThe signs of the experimental values were derived from a comparison of Ao,calc with the experimental Ao. 
d│Ao,calc│ = │(Ax + Ay + Az) / 3│ 
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Legends to Figures 
 
Scheme 1. 4-hydroxy-5-methyl-3-pyridinecarboxylic acid (DQ5) and 1,5-dimethyl-4-
hydroxy-3-pyridinecarboxylic acid (DQ715) shown in their fully protonated forms (H3L+ and 
H2L+, respectively) 
 
Fig. 1. Low-field region of the 1H NMR spectra of the ligands at the indicated pH values at T 
= 298 K (a, b) and T = 280 K (c) (cDQ5 = 1.1 × 10–3 mol/dm3, cDQ715 = 2 × 10–3 mol/dm3 
I = 0.2 mol/dm3(KCl)) 
 
Fig. 2. Left: pH-potentiometric titration curves with the fitted curves (with continuous line) 
for ligands and for the copper(II)–ligands systems at different metal-to-ligand concentration 
ratios. Right: distribution diagrams of the most important Cu(II) species in the presence of: 
(a) DQ5; cCu(II) = 5 × 10–4 mol/dm3, cDQ5 = 1 × 10–3 mol/dm3 
(b) DQ715; cCu(II) = 1 × 10–3 mol/dm3, cDQ715 = 2 × 10–3 mol/dm3 
(I = 0.2 mol/dm3 (KCl), T = 298 K) 
 
Fig. 3. Spectrophotometric absorbance curves of the Cu(II) – DQ715 system at various pH 
values; cCu(II) = 4×10–5 mol/dm3, cDQ715 = 8×10–5 mol/dm3. The inset shows the change in the 
absorbance the fitted curves were calculated (with dashed line) at 268 nm as function of the 
pH (I = 0.2 mol/dm3 (KCl), T = 298 K) 
 
Fig. 4. (a) pH dependent series of experimental (black) and simulated (gray) EPR spectra 
(cDQ715 = 2 × 10-3 mol/dm3, cCu = 1 × 10-3 mol/dm3, I = 0.2 mol/dm3 (KCl) T = 298 K), and (b) 
calculated component EPR spectra obtained by the „two-dimensional” simulation 
 
Fig. 5. Distribution diagrams of the most important Zn(II) species in the presence of  
(a) DQ5; cZn(II) = 5 × 10-4 mol/dm3, cDQ5 = 1 × 10-3 mol/dm3 
(b) DQ715; cZn(II) = 1 × 10-3, cDQ715 = 2 × 10-3 mol/dm3 
(I = 0.2 mol/dm3 (KCl) T = 298 K) 
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Fig. 6. Calculated and experimental 1H NMR shifts of the of N-CH-C-COO hydrogen of 
DQ715 as a function of the pH in Zn(II)–DQ715 system (cDQ715 = 2 × 10–3 mol/dm3 I = 0.2 M 
(KCl) T = 298 K) 
Fig. 7. Cytotoxicity profile of CuCl2 and DQ715. HEK-293 cells were treated for 24 h with 
increasing concentrations of CuCl2 (●) or DQ715 (○). Cytotoxicity was evaluated by the MTT 
test. IC50 values were calculated by four parameter logistic model (P < 0.05). Values are 
shown as the means (±SD) of five independent experiments 
 
Fig. 8. Effect of Cu(II) and DQ715 combined treatment. HEK-293 cells were treated for 24 h 
with 0.15 mmol/dm3 of CuCl2 and then washed twice with PBS, and re-incubated with fresh 
complete medium (black) or medium added with increasing concentration of DQ715 (white), 
for further 24 h before MTT determination. Values are shown as the means (±SD) of five 
independent  experiments 
